On 10 September, Swiss 3PL Kuehne + Nagel (K+N) announced that “with the opening of airside pharma & healthcare hubs in Brussels, Belgium, and Johannesburg, South Africa,” it “adds two strategic elements to its global GxP-certified network of temperature-controlled facilities for the distribution of vaccines and other pharma & healthcare products.”

This in a world where vaccine prototypes may or may not work and where air is tight and ...

Subscription Required

In order to view the entire article please either register an account and subscribe or login with a valid subscription below

Please Register

Please either or click register below to continue Register